Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, on what basis (a) Omega Diagnostics, (b) SureScreen and (c) Global Access Diagnostics were chosen for contracts to produce lateral flow devices for covid-19.

SureScreen, Global Access Diagnostics and Omega were selected via targeted engagement with the wider United Kingdom testing industry. This engagement was coordinated via the Rapid Antigen Consortium – an open forum bringing together UK companies with applicable experience and expertise. Due diligence and relevant commercial processes were applied prior to the contract award.